Skip header and navigation

Refine By

493 records – page 1 of 50.

The 2nd international workshop 'Novel Therapeutic Strategies in Cancer' in St-Petersburg.

https://arctichealth.org/en/permalink/ahliterature116919
Source
Cell Death Dis. 2013;4:e475
Publication Type
Conference/Meeting Material
Article
Date
2013

A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.

https://arctichealth.org/en/permalink/ahliterature162371
Source
Biol Blood Marrow Transplant. 2007 Aug;13(8):956-64
Publication Type
Article
Date
Aug-2007
Author
Mitchell Sabloff
Harold L Atkins
Isabelle Bence-Bruckler
Christopher Bredeson
Dean Fergusson
Paul Genest
Harry Hopkins
Brian Hutton
Sheryl Mcdiarmid
Lothar B Huebsch
Author Affiliation
The Ottawa Hospital Blood and Marrow Transplant Program, University of Ottawa, Ottawa, Ontario, Canada. msabloff@ottawahospital.on.ca
Source
Biol Blood Marrow Transplant. 2007 Aug;13(8):956-64
Date
Aug-2007
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Disease-Free Survival
Female
Hematopoietic Stem Cell Transplantation - adverse effects - methods
Humans
Longitudinal Studies
Lymphoma, Follicular - therapy
Male
Middle Aged
Neoplasm Recurrence, Local - therapy
Ontario
Retrospective Studies
Salvage Therapy - methods
Transplantation, Autologous - methods
Abstract
Autologous stem cell transplant (ASCT) has been shown to be an effective treatment for follicular lymphoma (FL). We explored our experience in ASCT for FL among all patients treated over a 15-year period from diagnosis through their entire treatment history including relapse post ASCT. All patients who underwent an unpurged ASCT for relapsed, advanced FL between June 1990 and December 2000 were analyzed. After salvage therapy they received melphalan/etoposide/total body irradiation, BCNU, etoposide, cytarabine, melphalan (BEAM), or cyclophosphamide BCNU etoposide (CBV) as conditioning for the ASCT. One hundred thirty-eight patients with a median age of 48 years and a median follow-up of 7.6 years were analyzed. The majority were of the subtype grade 1, nontransformed (FL-NT), having had 1 prior chemotherapy. The progression-free (PFS) and overall survival (OS) of the FL-NT at 10 years were 46% and 57%, respectively, and at 5 years for the transformed (FL-T) were 25% and 56%, respectively, of which only the PFS was significantly different (P=.007). The median OS from diagnosis was 16 years for the FL-NT. ASCT positively altered the trend of shorter remissions with subsequent chemotherapies, and there was no difference in OS between those who had 1, 2, or >2 chemotherapies prior to ASCT. Salvage therapy for relapse post ASCT was effective (OS>1 year) in a third of patients. Unpurged ASCT is an effective tool in the treatment of relapsed, aggressive FL-NT and FL-T, is superior to retreatment with standard chemotherapy, is effective at various stages of treatment, is likely to have a beneficial influence on the natural history of this disease, and the disease is amenable to salvage therapy post-ASCT relapse.
PubMed ID
17640600 View in PubMed
Less detail

(137)Cs distributions in soil and trees in forest ecosystems after the radioactive fallout - Comparison study between southern Finland and Fukushima, Japan.

https://arctichealth.org/en/permalink/ahliterature281005
Source
J Environ Radioact. 2016 Sep;161:73-81
Publication Type
Article
Date
Sep-2016
Author
Jukka Pumpanen
Mizue Ohashi
Izuki Endo
Pertti Hari
Jaana Bäck
Markku Kulmala
Nobuhito Ohte
Source
J Environ Radioact. 2016 Sep;161:73-81
Date
Sep-2016
Language
English
Publication Type
Article
Keywords
Cesium Radioisotopes - analysis
Chernobyl Nuclear Accident
Cryptomeria
Finland
Fukushima Nuclear Accident
Japan
Pinus
Plant Leaves - chemistry
Plant Stems - chemistry
Radioactive fallout
Soil Pollutants, Radioactive - analysis
Trees - chemistry
Abstract
The nuclear accidents at Chernobyl and Fukushima released large amounts of (137)Cs radionuclides into the atmosphere which spread over large forest areas. We compared the (137)Cs concentration distribution in different parts of two coniferous forest ecosystems (needle litter, stems and at different depths in the soil) over short and long term periods in Finland and Japan. We also estimated the change in (137)Cs activity concentrations in needle and soil between 1995 and 2013 in Southern Finland based on the back-calculated (137)Cs activity concentrations. We hypothesized that if the (137)Cs activity concentrations measured in 1995 and 2013 showed a similar decline in concentration, the (137)Cs activity concentration in the ecosystem was already stable in 1995. But if not, the (137)Cs activity concentrations were still changing in 2013. Our results showed that the vertical distribution of the (137)Cs fallout in the soil was similar in Hyytiälä and Fukushima. The highest (137)Cs concentrations were observed in the uppermost surface layers of the soil, and they decreased exponentially deeper in the soil. We also observed that (137)Cs activity concentrations estimated from the samples in 1995 and 2013 in Finland showed different behavior in the surface soil layers compared to the deep soil layer. These results suggested that the (137)Cs nuclei were still mobile in the surface soil layers 27 years after the accident. Our results further indicated that, in the aboveground parts of the trees, the (137)Cs concentrations were much closer to steady-state when compared to those of the surface soil layers based on the estimated declining rates of (137)Cs concentration activity in needles which were similar in 1995 and 2013. Despite its mobility and active role in the metabolism of trees, the (137)Cs remains in the structure of the trees for decades, and there is not much exchange of (137)Cs between the heartwood and surface layers of the stem.
PubMed ID
27158060 View in PubMed
Less detail

Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia.

https://arctichealth.org/en/permalink/ahliterature23997
Source
Cancer Res. 1993 Jul 1;53(13):3008-14
Publication Type
Article
Date
Jul-1-1993
Author
H M el-Beltagi
A C Martens
P. Lelieveld
E A Haroun
A. Hagenbeek
Author Affiliation
Department of Hemato-Oncology TNO, Erasmus University Rotterdam, The Netherlands.
Source
Cancer Res. 1993 Jul 1;53(13):3008-14
Date
Jul-1-1993
Language
English
Publication Type
Article
Keywords
Administration, Oral
Animals
Antineoplastic Agents - pharmacology
Bone Marrow - drug effects
Bone Marrow Cells
Cell Differentiation - drug effects
Cell Survival - drug effects
Clone Cells
Comparative Study
Disease Models, Animal
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Evaluation
Drug Screening Assays, Antitumor
Hematopoietic Stem Cells - cytology - drug effects
Leukemia, Myelocytic, Acute - drug therapy - pathology
Male
Phenylenediamines - pharmacology
Rats
Rats, Inbred BN
Research Support, Non-U.S. Gov't
Tumor Cells, Cultured
Abstract
Acetyldinaline [CI-994; GOE 5549; PD 123 654; 4-acetylamino-N-(2'-aminophenyl)-benzamide] is the acetylated derivative form of the original compound Dinaline (GOE 1734; PD 104 208). The efficacy and toxicity of Acetyldinaline for remission-induction treatment of leukemia were evaluated and compared with those observed in previous studies of Dinaline in the Brown Norway acute myelocytic leukemia, as a preclinical model for human acute myelocytic leukemia. There were three treatment groups. Leukemic animals received either 1 or 2 courses of 5 daily p.o. administrations of Acetyldinaline with a "full dose" of 23.7 mg/kg once daily (first group), a twice daily "half dose" of 11.85 mg/kg with an interval of 8 h (second group), or a "half dose" of 11.85 mg/kg once daily (third group). The drug-free interval between the 2 courses was 2 or 9 days. With repeated daily p.o. administrations of 23.7 mg/kg either in a single daily dose or a split daily dose of 2 x 11.85 mg/kg for 1 course, at least an 8-log leukemic cell kill was achieved. In contrast, with these treatment schedules, less than a 1-log cell kill of normal pluripotent hemopoietic stem cells (CFU-S) in the femoral bone marrow was found. Split daily dose treatment was more effective resulting in 37.5% cures, while no cures were observed with the single daily treatment for one course. Treatment with single daily dose of 23.7 mg/kg or a split daily dose of 2 x 11.85 mg/kg for 2 courses, with either a 2- or 9-day interval in between, resulted in lethal toxicity in most of rats. This result was comparable with that previously observed after equimolar doses of Dinaline (20 mg/kg). The half-dose once daily treatment with Acetyldinaline (11.85 mg/kg) for 1 or 2 cycles resulted in about a 4.5 or > 8-log leukemic cell kill, respectively. Toxic side effects, i.e., damage to the gastro-intestinal tract and hemorrhages in the lungs, were more pronounced with full dose either in the single or the split daily dose regimen. No significant toxicity was observed at the half-dose treatment once daily. In conclusion, the impressive differential activity against leukemic cells and normal stem cells observed in this relevant rat model for human acute myelocytic leukemia warrants the introduction of this compound in clinical phase I/II studies.
PubMed ID
8319208 View in PubMed
Less detail

Acoustic-reflex responses in patients with insulin-dependent diabetes mellitus.

https://arctichealth.org/en/permalink/ahliterature48476
Source
Am J Otolaryngol. 1994 Mar-Apr;15(2):109-13
Publication Type
Article
Author
J. Virtaniemi
M. Laakso
J. Nuutinen
S. Karjalainen
E. Vartiainen
Author Affiliation
Department of Otolaryngology, University of Kuopio, Finland.
Source
Am J Otolaryngol. 1994 Mar-Apr;15(2):109-13
Language
English
Publication Type
Article
Keywords
Acoustic Impedance Tests
Adult
Auditory Threshold - physiology
Autonomic Nervous System - physiology
Autonomic Nervous System Diseases - physiopathology
Blood Glucose - analysis
Comparative Study
Diabetes Mellitus, Type 1 - blood - drug therapy - metabolism - physiopathology
Diabetic Angiopathies - physiopathology
Diabetic Neuropathies - physiopathology
Evoked Potentials, Auditory, Brain Stem - physiology
Female
Hemoglobin A, Glycosylated - analysis
Humans
Male
Reaction Time - physiology
Reflex, Acoustic - physiology
Reflex, Stretch - physiology
Research Support, Non-U.S. Gov't
Time Factors
Abstract
PURPOSE: Patients with insulin-dependent diabetes mellitus (IDDM) are especially susceptible to microangiopathic complications such as nephropathy, retinopathy, and neuropathy. Microangiopathic changes are also the most important findings in histopathologic studies of the inner ear and central nervous systems in diabetic subjects. No previous studies have measured acoustic-reflex latencies (ARL) or amplitudes (ARA) in patients with IDDM. ARL and ARA reflect the function of the acoustic-reflex arch. Furthermore, possible changes in the tympanic membrane, ossicular chain, and stapedius muscle may affect the shape of acoustic-reflex. SUBJECTS AND METHODS: Acoustic-reflex thresholds, latencies, and amplitudes were studied in 53 patients with IDDM and 42 randomly selected nondiabetic control subjects, aged between 20 and 40 years, using the Madsen Model ZO 73 Impedance Bridge (Madsen Electronics, Copenhagen, Denmark). Subjects with an abnormal tympanic membrane, conductive hearing loss, and known cause for hearing impairment eg, noise damage, were excluded from the study. RESULTS: There were no differences between control and diabetic subjects in the contralateral acoustic-reflex thresholds. In contrast, patients with IDDM had longer ARLs and decreased ARAs compared with those of control subjects. ARA amplitude had linear correlation with the amplitude of tympanogram, whereas ARL had no linear correlation with auditory brainstem latencies in the same study subjects. Acoustic-reflex responses in insulin-dependent diabetic patients were not associated with the duration of diabetes, metabolic control, microangiopathy, or neuropathy. CONCLUSIONS: Prolonged ARLs and decreased ARAs in patients with insulin-dependent diabetes are probably caused more by the stiff middle ear system than disturbances in the brainstem.
PubMed ID
8179101 View in PubMed
Less detail

Acute de novo Leukemia in Estonia and Western Sweden 1982-2006: Positive Trend in the Survival of Acute Leukemia over 25 Years.

https://arctichealth.org/en/permalink/ahliterature278078
Source
Acta Haematol. 2016;136(3):167-73
Publication Type
Article
Date
2016
Author
Erik Hulegårdh
Mari Punab
Erik Holmberg
Katrin Palk
Edward Laane
Hele Everaus
Lovisa Wennström
Dick Stockelberg
Source
Acta Haematol. 2016;136(3):167-73
Date
2016
Language
English
Publication Type
Article
Keywords
Acute Disease
Adolescent
Adult
Disease-Free Survival
Estonia - epidemiology
Female
Hematopoietic Stem Cell Transplantation
Humans
Leukemia - diagnosis - mortality - therapy
Male
Middle Aged
Prospective Studies
Retrospective Studies
Socioeconomic Factors
Survival Rate
Sweden - epidemiology
Abstract
This study focuses on the incidence, treatment, and survival of de novo acute leukemia in a 25-year perspective in western Sweden and Estonia. At the beginning of our study, Estonia was a part of the Eastern bloc with planned economy, but since 1991 it is a member of the European Union and transforming into a market economy. Survival rates have steadily increased in both countries. However, a gap between their survival curves remains. Based on our data, it is difficult to explain the big difference in the 5-year relative survival in favor of western Sweden (55 vs. 22%). In Germany, there was a big difference in overall cancer survival between East and West Germany after the fall of the iron curtain, but today no difference is seen. Differences in survival are probably due to a higher proportion of intense chemotherapy regimens and a higher rate of hematopoietic stem cell transplantations in Sweden. Other important factors might be better supportive care and diagnostics as well as better adjuvant therapy. Better staff training and conditions in wards are also factors that might play an essential role.
PubMed ID
27537981 View in PubMed
Less detail

Acute homing of bone marrow-derived mononuclear cells in intramyocardial vs. intracoronary transplantation.

https://arctichealth.org/en/permalink/ahliterature98984
Source
Scand Cardiovasc J. 2009 Dec;43(6):366-73
Publication Type
Article
Date
Dec-2009
Author
Jussi Mäkelä
Vesa Anttila
Kari Ylitalo
Reijo Takalo
Siri Lehtonen
Timo Mäkikallio
Eija Niemelä
Sebastian Dahlbacka
Jonne Tikkanen
Kai Kiviluoma
Tatu Juvonen
Petri Lehenkari
Author Affiliation
Department of Surgery, Oulu University Hospital, University of Oulu and Clinical Research Center, 90221, Oulu, Finland.
Source
Scand Cardiovasc J. 2009 Dec;43(6):366-73
Date
Dec-2009
Language
English
Publication Type
Article
Keywords
Animals
Bone Marrow Transplantation - methods
Cell Survival - drug effects
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic Stem Cells - physiology
Indium Radioisotopes - adverse effects - diagnostic use
Infusions, Intra-Arterial
Injections, Intramuscular
Myocardial Infarction - radionuclide imaging - surgery
Swine
Abstract
OBJECTIVES: Cell homing optimisation after transplantation is critical in myocardial infarction (MI) cell therapy. DESIGN: Eight pigs were randomized to receiving autologous purified (111)indium-labeled bone marrow mononuclear cells (BMMCs) (10(8) cells/2 ml) by intramyocardial (IM) (n=4) or by intracoronary (IC) (n=4) transplantation after 90 minutes occlusion of the CX-coronary artery. Dual isotope SPECT imaging was performed 2 and 24 hours postoperatively. Two animals were additionally analyzed on the sixth postoperative day. Tissue samples from the major organs were analyzed. RESULTS: In SPECT imaging revealed that BMMCs administered using IM injection remained in the injured area. In contrast, minor proportion of IC transplanted cells remained in the myocardium, as most of the cells showed homing in the lungs. Analysis of the biopsies showed a seven-fold greater number of cells in the myocardium for the IM method and a 10-fold greater number of cells in the lungs in the IC group (p
PubMed ID
19544220 View in PubMed
Less detail

[Acute kidney injury and tubular biomarkers after hematopoietic stem cell transplantation].

https://arctichealth.org/en/permalink/ahliterature275530
Source
Ter Arkh. 2016;88(6):14-20
Publication Type
Article
Date
2016
Author
V A Dobronravov
K A Smirnov
B V Afanas'ev
O V Galkina
A V Smirnov
Source
Ter Arkh. 2016;88(6):14-20
Date
2016
Language
Russian
Publication Type
Article
Keywords
Acute Kidney Injury - diagnosis - etiology - metabolism - physiopathology
Adult
Biomarkers - blood
Chemokine CCL2 - blood
Female
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Kidney Function Tests
Kidney Tubules - metabolism - pathology - physiopathology
Male
Membrane Glycoproteins - blood
Middle Aged
Predictive value of tests
Prospective Studies
Receptors, Virus - blood
Reproducibility of Results
Russia
Abstract
To determine the value of molecular biomarkers (BMs) associated with tubular epithelial damage in developing and predicting acute kidney injury (AKI) after hematopoietic stem cell transplantation (HSCT).
The open-label observational prospective study enrolled 90 patients (46 males and 44 females) who had undergone HSCT. The concentrations of BMs (calbindin, clusterin, interleukin-18 (IL-18), kidney injury molecules-1 (KIM-1), glutathione S-transferase-p (GST-p), and monocyte chemoattractant protein-1 (MCP-1) were measured in urinary samples 7 days before HSCT (week 0) and at weeks 1, 2, 3, 4, and 5. Main clinical parameters were simultaneously monitored. AKI was diagnosed and stratified according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines.
At weeks 1, 2, 3, 4, and 5 after HSCT, the proportion of AKI cases was 7.8, 8.9, 12.5, 27.3, and 35.9%, respectively. The elevated urinary levels of BMs (above the median) were found to be substantially more common than AKI cases. The urinary excretion of the majority of BMs dramatically increased in the early HSCT period. The median number of simultaneously elevated BMs was 3 (2; 5) during the entire follow-up period. Clusterin, MCP-1 and KIM-1 positively and significantly correlated with serum creatinine at the week following the determination of BMs in the multivariate linear regression models adjusted for other confounders. The higher urinary KIM-1 and/or MCP-1 excretion regardless of other clinical indicators was associated with the higher relative risk (RR) of AKI, which increased by 2.3 times with a rise in one of these indicators and by 3.4 times with a rise in both indicators.
Multiple renal toxic effects after HSCT result in a substantial and simultaneous elevation of urinary excretion of BMs for tubular damage. Among the BMs studied, KIM-1 and MCP-1 seem to be the most suitable molecules for assessing the risk of AKI in this cohort of patient within the predictive diagnostic approach.
PubMed ID
27296256 View in PubMed
Less detail

493 records – page 1 of 50.